VIA vs DBD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

VIA

44.2
AI Score
VS
DBD Wins

DBD

45.7
AI Score

Investment Advisor Scores

VIA

44score
Recommendation
HOLD

DBD

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric VIA DBD Winner
Revenue 263.14M 1.82B DBD
Net Income -39.70M 20.50M DBD
Gross Margin 40.2% 24.8% VIA
Net Margin -15.1% 1.1% DBD
Operating Income -45.34M 90.00M DBD
ROE -6.4% 2.1% DBD
ROA -5.5% 0.5% DBD
Total Assets 718.35M 3.74B DBD
Current Ratio 5.05 1.27 VIA

Relative Price Performance (Last 90 Days)

VIA 1M: +2.8% · 3M: +74.5% DBD 1M: -8.6% · 3M: -19.6%

Current Technical Phase

VIA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (24.9% over 20 days), RSI 51

RSI (14): 51.2 · Price: $25.76

DBD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.1%), weak momentum, RSI 35

RSI (14): 34.5 · Price: $65.62

Fundamentals Snapshot

Metric VIA DBD
Market Cap
Forward P/E 59.9 9.4
Trailing P/E 22.1
Revenue (TTM)
Revenue Growth 0.3% 0.0%
Gross Margin 0.4% 0.3%
Operating Margin -0.2% 0.1%
EPS -2.98 2.96
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, DBD is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.